Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: Role of the C-5 group in target specificity

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 582-585

  Morris, Julia E ^a   Pan, Xiao Su ^a   Fisher, L Mark ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 (3 METHYL 1 PIPERAZINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; GENE PRODUCT; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PEFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM MUTANT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DRUG DELIVERY SYSTEMS; FLUOROQUINOLONES; MOLECULAR CONFORMATION; PIPERAZINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0036150162     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.582-585.2002     Document Type: Article

References (32)

1. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
2. Community-acquired pneumonia
3. DNA gyrase, topoisomerase IV, and the 4-quinolones
4. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins
5. Primary targets of fluoroquinolones in Streptococcus pneumoniae
6. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
7. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
8. DNA gyrase: An enzyme that introduces superhelical turns into DNA
9. Activity of the new fluoroquinolone troyafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
10. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro
11. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
12. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase A subunit: Effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth
13. DNA gyrase action involves the introduction of transient double-strand breaks into DNA
14. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
15. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones
16. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
17. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
19. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae: Role in fluoroquinolone resistance
20. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
21. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
22. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
23. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: Mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins
24. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
25. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
26. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
27. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin
28. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
29. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: Correlation with penicillin resistance
30. ParC and GyrA may be interchangeable initial targets of some quinolones in Streptococcus pneumoniae
31. DNA topoisomerases
32. Antibacterial activity of grepafloxacin